000 01308 a2200385 4500
005 20250513123741.0
264 0 _c19970929
008 199709s 0 0 eng d
022 _a0362-5664
024 7 _a10.1097/00002826-199708000-00008
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aDeutsch, S I
245 0 0 _aMethylene blue adjuvant therapy of schizophrenia.
_h[electronic resource]
260 _bClinical neuropharmacology
_cAug 1997
300 _a357-63 p.
_bdigital
500 _aPublication Type: Clinical Trial; Journal Article
650 0 4 _aAdult
650 0 4 _aEnzyme Inhibitors
_xtherapeutic use
650 0 4 _aGuanylate Cyclase
_xantagonists & inhibitors
650 0 4 _aHumans
650 0 4 _aMale
650 0 4 _aMethylene Blue
_xtherapeutic use
650 0 4 _aMiddle Aged
650 0 4 _aNitric Oxide
_xantagonists & inhibitors
650 0 4 _aPsychiatric Status Rating Scales
650 0 4 _aSchizophrenia
_xdrug therapy
650 0 4 _aSchizophrenic Psychology
700 1 _aRosse, R B
700 1 _aSchwartz, B L
700 1 _aFay-McCarthy, M
700 1 _aRosenberg, P B
700 1 _aFearing, K
773 0 _tClinical neuropharmacology
_gvol. 20
_gno. 4
_gp. 357-63
856 4 0 _uhttps://doi.org/10.1097/00002826-199708000-00008
_zAvailable from publisher's website
999 _c9240357
_d9240357